Role and implications of nanodiagnostics in the changing trends of clinical diagnosis  by Alharbi, Khalid Khalaf & Al-sheikh, Yazeed A.
Saudi Journal of Biological Sciences (2014) 21, 109–117King Saud University
Saudi Journal of Biological Sciences
www.ksu.edu.sa
www.sciencedirect.comREVIEWRole and implications of nanodiagnostics
in the changing trends of clinical diagnosis* Corresponding author. Tel.: +966 567288142; fax: +966 114693630.
E-mail address: kharbi@ksu.edu.sa (K.K. Alharbi).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
1319-562X ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
http://dx.doi.org/10.1016/j.sjbs.2013.11.001Khalid Khalaf Alharbi *, Yazeed A. Al-sheikhDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219,
Riyadh 11433, Saudi ArabiaReceived 16 September 2013; revised 3 November 2013; accepted 3 November 2013
Available online 19 November 2013KEYWORDS
Nanodiagnostics;
PCR;
DNA sequencingAbstract Nanodiagnostics is the term used for the application of nanobiotechnology in molecular
diagnosis, which is important for developing personalized cancer therapy. It is usually based on
pharmacogenetics, pharmacogenomics, and pharmacoproteomic information but also takes into
consideration environmental factors that inﬂuence response to therapy. Nanotechnology in
medicine involves applications of nanoparticles currently under development, as well as longer
range research that involves the use of manufactured nano-robots to make repairs at the cellular
level. Nanodiagnostic technologies are also being used to reﬁne the discovery of biomarkers, as
nanoparticles offer advantages of high volume/surface ratio and multifunctionality. Biomarkers
are important basic components of personalized medicine and are applicable to the management
of cancer as well. The ﬁeld of nano diagnostics raises certain ethical concerns related with the testing
of blood. With advances in diagnostic technologies, doctors will be able to give patients complete
health checks quickly and routinely. If any medication is required this will be tailored speciﬁcally to
the individual based on their genetic makeup, thus preventing unwanted side-effects.
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Nanotechnology is already starting to have an impact on the
diagnosis, treatment and prevention of disease, especially by
enabling early disease detection and diagnosis, as well as pre-
cise and effective therapy (Buxton et al., 2003). Its applications
are seen in surgery, cancer diagnosis and therapy, bio-detec-
tion of molecular disease markers, molecular imaging, implant
technology, tissue engineering, and devices for drug, protein,
and gene and radionuclide delivery. Nano-materials are struc-
turally and functionally prevalent in the organic, inorganic,
and biological ﬁelds. Their unique size-dependent properties
make these materials superior and indispensable in many areas
of human activity. Nanotechnology is of great use for medical
diagnosis and various nanoparticles have exhibited tremen-
dous potential for detecting disease markers, pre-cancerous
cells, fragment of viruses, speciﬁc proteins, antibodies and
other indicators of disease. Many of the developments have al-
ready started and within a couple of years will show a deﬁnite
impact in the ﬁeld of diagnostics (Yezhelyev et al., 2006).
Nanotechnology will have an almost endless string of appli-
cations in biotechnology, biology, and biomedicine. New con-
cepts for regenerative medicine give hope to many patients
with organ failure or severe injuries. Nano-particle reinforced
polymers, orally applicable insulin, and artiﬁcial joints made
from nano-particulate materials, and low-calorie foods with
nano-particulate taste enhancers (Barnes et al., 2007; Radwant
and Aboul-Enein, 2002). Some products are already commer-
cially available, such as surgical blades and suture needles,
contrast-enhancing agents for magnetic resonance imaging,
bone replacement materials, wound dressings, anti-microbial
textiles, chips for in vitro molecular diagnostics, micro-cantile-
vers, and micro-needles. Nanotechnology and biology can ad-
dress several biomedical problems, and can revolutionize the
ﬁeld of health and medicine (Curtis and Wilkinson, 2001).
Nanotechnology is currently employed as a tool to explore
the darkest avenues of medical sciences in several ways like
imaging (Waren and Nie, 1998), sensing (Vaseashta and Dim-
ova-Malinovska, 2005), targeted drug delivery (Langer R
2001) and gene delivery systems (Roy et al., 1999) and artiﬁcial
implants (Sachlos et al., 2006). The new age drugs are nano-
particles of polymers, metals or ceramics, which can combat
conditions like cancer (Farokhzad et al., 2006) and ﬁght hu-
man pathogens like bacteria (Panacek et al., 2006; baker
et al., 2005). Novel therapeutic strategies include the develop-
ment of targeted transport vehicles allowing drug delivery to
speciﬁc cells or cell structures. Of particular interest are bioen-
gineered nano-particles, which can be utilized as transport
vehicles of diagnostic or therapeutic agents.1.1. Nanoparticles
Nanotechnologies represent an unprecedented recent advance
that may revolutionize many areas of medicine and biology,
including cancer diagnostics and treatment. In recent years
there has been a rapid increase in nanotechnology applications
in medicine in order to prevent and treat diseases in the human
body (Angeli et al., 2008). Nano-medicine (the application
nanotechnology to health) raises high expectations for millions
of patients for better, more efﬁcient and affordable healthcare
and has the potential of delivering promising solutions to
many illnesses. Nano-medicine, an offshoot of nanotechnol-
ogy, refers to highly speciﬁc medical intervention at the molec-
ular scale for curing disease or repairing damaged tissues
(Campbell et al., 2008), such as bone (Zou et al., 2008;
Mahony and Jones, 2008), muscle, nerve chronic pulmonary
diseases and coronary artery disease (Schoenhagen and
Conyers, 2008). Nanoparticle-based technologies have demon-
strated especially high potential for medical purposes, ranging
from diagnosing diseases to providing novel therapies.
However, to be clinically relevant, the existing nanoparticle-
based technologies must overcome several challenges, includ-
ing selective nanoparticle delivery, potential cytotoxicity,
imaging of nanoparticles, and real-time assessment of their
therapeutic efﬁcacy.
The size of nanomaterials is similar to that of most biolog-
ical molecules and structures; therefore, nanomaterials can be
useful for both in vivo and in vitro biomedical research and
applications (Curtis and Wilkinson, 2001). The integration of
nanomaterials with biology has led to the development of diag-
nostic devices, contrast agents, analytical tools, physical ther-
apy applications, and drug delivery vehicles. Nanoparticles
possess certain size-dependent properties, particularly with re-
spect to optical and magnetic parameters, that can be manip-
ulated to achieve a detectable signal. The primary event in
most nanoparticle-based assays is the binding of a nanoparti-
cle label or probe to the target biomolecule that will produce
a measurable signal characteristic of the target biomolecules.
A variety of probes have been used for this purpose, including
QDs, nanoshells, and metal nanoparticles, quantum dots QDs
are the most used and promising nanostructures for diagnostic
applications (West and Halas, 2003; Jain, 1998). QDs are semi-
conductor nanocrystals, characterized by strong light absor-
bance that can be used as ﬂuorescent labels for biomolecules.
New nanodiagnostic tools include carbon nanotubes, nano-
shells, gold nanoparticles, cantilevers and quantum dots
(QDs). QDs, which are the most promising nanostructures
for diagnostic applications, are semiconductor nanocrystals
characterized by high photostability, single-wavelength
Table 1 Types of nanodevices are used in clinical Application.
Signiﬁcance of Nanodiagnostics in Clinical Diagnosis 111excitation, and size-tunable emission (Hassan et al., 2006).
Different types of nanodevices are used for speciﬁc purposes
(Table 1).
Ranging from the nano- to femtoliter range; droplet-based
systems have also been used to directly synthesize particles and
encapsulate many biological entities for biomedicine and bio-
technology applications. This technology has the potential to
provide novel solutions for today’s biomedical engineering
challenges and for advanced diagnostics and therapeutics.
Nanowires could lead to the fabrication of more sophisti-
cated and high multispeciﬁcity biosensors via selective func-
tionalization of individual segments for medical diagnostic
applications. The surface of gold nanoparticles can be tailored
by ligand functionalization to selectively bind biomarkers
(Chandra et al., 2010). Thiol-linking of DNA and chemical
functionalization of gold nanoparticles for speciﬁc protein/
antibody binding are the most common approaches. Simple
and inexpensive methods based on these bio-nanoprobes were
initially applied for the detection of speciﬁc DNA sequences
and are presently being expanded to perform a number of clin-
ical diagnostic tests.
Nanoengineering of the coated colloids and microcapsules
allows precision control over optical, mechanical, and catalytic
properties to achieve sensitive response using a combination of
polymers, ﬂuorescent indicators, and glucose-speciﬁc proteins.
Many of these nanodevices are available commercially and
need to be adapted for the purpose required.2. Nanotechnology in diagnosis of a number of diseasesMost of the current work was being done for diagnosing can-
cer but now it is being extended to other diseases. Nanodiag-
nostics, deﬁned as the use of nanotechnology for clinical
diagnostic purposes (Jain, 1998), was developed to meet the
demands of clinical diagnostics for increased sensitivity and
earlier detection of disease. The increased demand for sensitiv-
ity requires that a diagnostically signiﬁcant interaction occurs
between analyzed molecules and signal-generating particles,
thus enabling the detection of a single analyzed molecule. Nan-
odevices can be used for in vitro or in vivo diagnosis where it is
coupled with existing imaging technology.
Nanoparticles are considered to have the potential as novel
intravascular or cellular probes for both diagnostic (imaging)
and therapeutic purposes (drug/gene delivery), which is ex-
pected to generate innovations and play a critical role in med-
icine (Singh et al., 2007). Target-speciﬁc drug/gene delivery
and early diagnosis in cancer treatment is one of the priority
research areas in which nanomedicine will play a vital role.
Some recent breakthroughs in this ﬁeld recently also proved
this trend. It is of great importance in the treatment and diag-
nosis of cancer. Some recent breakthroughs in the form of
drug delivery are effective target therapies used in pre-sympat-
homimetic and diagnosis techniques (Torchilin, 2007). Biomol-
ecule coated ultra small super paramagnetic iron oxide
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be safely injected into the blood stream of the patients and
the presence of speciﬁc antigens/target molecular markers on
the particles bind to the positive cells which induce a speciﬁc
signal that can be detected by MRI (magnetic resonance imag-
ing). Nanomaterials with a variety of unique intrinsic physical
properties have attracted growing interest for use in biomedi-
cal imaging applications (Cho et al., 2010; Lee et al., 2011).
Among the imaging nanoprobes, magnetic iron oxide nano-
particles have been widely used as MRI contrast agents for
cancer imaging, helping to provide anatomical details and fur-
thermore real-time monitoring of the therapeutic response
(Kievit and Zhang, 2011; Varadan et al., 2008). This technol-
ogy will help in detecting individual cancer cells months or
years earlier than the conventional diagnostic tools. This will
also be used for detecting residual or metastatic cancer cells
after therapy.
Multilayer ﬁlms and capsules synthesized from DNA have
great potential as they are biodegradable, biocompatible, and
the structure of the ﬁlms can be ﬁnely controlled by base pair-
ing of the nucleotides (Angus et al., 2008). These DNA cap-
sules are envisaged to ﬁnd applications in diagnosis of not
only cancer but various other diseases which have speciﬁc
known biomarkers.
Optical tweezers is one of the nano manipulation tech-
niques, which can investigate pico-newton to femto-newton
forces exerted on microscopic objects. With the Cell palpationFigure 1 Nanoscale cantilevers concsystem by use of optical tweezers an operator manipulates a
probe particle that touches a certain location of a cell and feels
the strength of the cell through a haptic device, which displays
the force calculated and generated in a computer. This tech-
nique can be used in the differential diagnosis of tissue
growths, calculi, cysts, abscess, as well as in hepato and spleno
– megaly.
The newest technologies within nanodiagnostics involve
microﬂuidic or ‘‘lab on a chip’’ systems, in which the DNA
sample is completely unknown. The idea behind this kind of
chip is impel: the combination of numerous processes of
DNA analysis are combined on a single chip composed of a
single glass and silicon substrate (Burns, 1998). The device it-
self is composed of micro fabricated luidic channels, heaters,
temperature sensors, electrophoretic chambers, and ﬂuores-
cence detectors to analyze nanoliter-sized DNA samples
(O’Connor, 2005). Droplet-based microﬂuidic systems have
been shown to be compatible with many chemical and biolog-
ical reagents and are capable of performing a variety of ‘‘dig-
ital ﬂuidic’’ operations that can be rendered programmable
and reconﬁgurable. This platform has dimensional scaling ben-
eﬁts that have enabled controlled and rapid mixing of ﬂuids in
the droplet reactors, resulting in decreased reaction times.
Coupled with the precise generation and repeatability of drop-
let operations, has made the droplet-based microﬂuidic system
a potent high throughput platform for in vitro diagnostics.
Microﬂuidic technologies illustrate a possible route for theept explained by cancer markers.
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for disease staging and monitoring (Walt, 2005).
Nanoscale cantilevers, microscopic, excitable beams resem-
bling a row of diving boards, are built using semiconductor
lithographic techniques. These can be coated with molecules
capable of binding speciﬁc substrates––DNA complementary
to a speciﬁc gene sequence. Such micron-sized devices, com-
prising many nanometer-sized cantilevers, can detect single
molecules of DNA or protein. Nanoscale cantilevers, con-
structed as part of a larger diagnostic device, can provide rapid
and sensitive detection of a number of disease speciﬁc mole-
cules (Raiteri et al., 2001; Carrascosa et al., 2006).
In the Fig. 1, below the concept is explained by taking the
example of cancer markers.
Similarly DNA-coated gold nanoparticles (NPs) can be
used for developing tests more sensitive than ELISA. When
the antigen is present in a complex protein mix, such as in ser-
um-containing culture medium or in crude body ﬂuids, and
analyzed in a sandwich assay, Nano-i PCR and i PCR usually
detect the antigen with 1–3 orders higher sensitivity than ELI-
SA (Adler and Wacker, 2003; Chen et al., 2009; Perez et al.,
2011) The basis of this system which uses larger magnetic mi-
cro particles (MMPs) to detect attomolar (10–18) concentra-
tions of serum proteins is represented in Fig. 2. In this case,
a monoclonal antibody to prostate speciﬁc antigen (PSA) is at-
tached to the MMP, creating a reagent to capture free PSA. A
second antibody to PSA, attached to the NPs, is then added,
creating a ‘‘sandwich’’ of the captured protein and two parti-
cles that are easily separated using a magnetic ﬁeld.
DNA-labeled magnetic nanobeads have the potential to
serve as a versatile foundation for detecting virtually any pro-
tein or nucleic acid with far more sensitivity than is possible
with conventional methods now in use. If this proves to be a
general property of such systems, nanoparticle-based diagnos-
tics could provide the means of turning even the rarest bio-
markers into useful diagnostic or prognostic indicators.
‘‘Smart’’ dynamic nanoplatforms have the potential to
change the way diseases are diagnosed, treated, and prevented.
The outside of such ‘‘nanoclinics’’ could have marker speciﬁc
monoclonal antibodies coated with polyethylene glycolFigure 2 DNA lab(PEG) to shield the device from immune system detection.
The polymer matrix of such particles could be loaded with
contrast agents, which would provide enhanced sensitivity
for pinpointing the location of the problem within the body,
and various types of therapeutic agents, such as reactive oxy-
gen-generating photodynamic sensitizers that would be acti-
vated once the particle detects a malignant or abnormal cell
could be developed
Dendrimers, 1- to 10-nm spherical polymers of uniform
molecular weight made from branched monomers, are proving
particularly adept at providing multifunctional modularity.
Dendrimers can serve as versatile nanoscale platforms for cre-
ating multifunctional devices capable of detecting a number of
proteins which are currently detected by individual ELISA test
example Thyroid proﬁle, Panel of Steroid hormones, Panel of
inﬂammatory Cytokines (Chen and Kendler, 2008).
Circulating peptides and protein fragments are shed from
all cell types in the tissue microenvironment, these vary in
health and disease, as well as at different phases of our physi-
ology. Proteolytic cascades within the tissue generate frag-
ments that diffuse into the circulatory system. The identity
and cleavage pattern of the peptides provide diagnostic infor-
mation and these nanosensors can be used to understand the
biological alterations in complex diseases like diabetes, asth-
ma, cardiovascular diseases and cancer.
Diagnostics based on altered DNA sequence detection uses
single-stranded oligonucleotide tagged magnetic nanobeads
(de la Torre et al., 2011). The target DNA is recognized and
volume-ampliﬁed to large coils by circularization of linear pad-
lock probes through probe hybridization and ligation, fol-
lowed by rolling circle ampliﬁcation (RCA) (Stro¨mberg
et al., 2008). Upon hybridization of the nanobeads in the
RCA coils, the complex magnetization spectrum of the beads
changes dramatically, induced by the attached volume-ampli-
ﬁed target molecules. This magnetization spectrum of the nan-
obeads can be used for concentration determination of RCA
coils down to the pM range, thus creating the opportunity
for nonﬂuorescence-based cost-efﬁcient high-sensitivity
diagnostics tool, more sensitive than PCR. This is useful for
all genetic disorders like thalassemia, cystic ﬁbrosis, musculareled nano beads.
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these SNP analysis gives an indication of susceptibility to com-
plex diseases especially CVD, diabetes mellitus, HTN, etc. and
is used for the prevention and management of these
conditions.
2.1. Detection of disease genes
DNA-based electrochemical sensors offer sensitivity, selectiv-
ity and low cost for the detection of mutated genes associated
with human disease (Drummond et al., 2003). All such sensors
exploit nanoscale interactions between the target in solution,
the recognition layer and a solid electrode surface. One of
the innovations is in electrochemical ampliﬁcations with nano-
particles. Proof of principle, reproducibility, and the robust,
simple and rapid characteristics of Clear Read nanoparticle
technology have been used with unampliﬁed DNA samples
to demonstrate all possible forms of three genes implicated
in hyper coagulation disorders.
2.2. Detection of single nucleotide polymorphisms
Nanosphere’s Clear Read nanoparticle technology enables a
microarray-based method for multiplex single nucleotide poly-
morphisms (SNP) genotyping in total human genomic DNA
without the need for target ampliﬁcation by PCR. This direct
SNP genotyping method requires no enzymes and relies on the
high sensitivity of the gold nanoparticle probes. Clear Read
technology sandwiches a target DNA SNP segment between
two oligonucleotide sequences to greatly increase detection
speciﬁcity and sensitivity. One segment identiﬁes any muta-
tions in the DNA and the probe, a highly sensitive gold nano-
particle, creates a strong signal accurately indicating the
presence of a speciﬁc target SNP (Bao et al., 2005). The assay
format is simple, rapid and robust pointing to its suitability for
multiplex SNP proﬁling at the point of care. Recently 20 Nan
cantilevers labeled with 20 ﬂuorescence dyes were able to de-
tect multiple SNP’s at the same time.
2.2.1. Glucose monitoring in vivo by nanosensors
It is possible to engineer ﬂuorescent micro/nanoscale devices
for glucose sensing. Deployment of micro/nanoparticles in
the dermis may allow transdermal monitoring of glucose
changes in the interstitial ﬂuid.
Non-invasive glucose sensing will maximize acceptance by
patients and overcome biocompatibility problems of implants.
A new type of optical nanosensor, based on single walled car-
bon nanotubes that modulate their emission in response to the
adsorption of speciﬁc biomolecules, can be used as a glucose
sensor (Mano and Heller, 2005). Carbon nanotubes are coated
with glucose oxidase, an enzyme that breaks down glucose
molecules. Then ferricyanide, an electron-hungry molecule, is
sprinkled, onto the nanotubes’ surfaces (Zhang et al., 2005).
Ferricyanide draws electrons from the nanotubes, quenching
their capacity to glow when excited by infrared light. When
glucose is present, it reacts with the oxidase, producing hydro-
gen peroxide. In turn, hydrogen peroxide reacts with ferricya-
nide in a way that reduces that molecule’s hunger for electrons.
The higher the glucose level, the greater is the nanotube’s
infrared ﬂuorescence. This will monitor glucose continuously
without multiple sample collection.2.2.2. Nanotechnology and Diagnosis of infectious disease
Nanotechnology is research at the atomic, molecular, or mac-
romolecular scale using nanomaterials that have a length scale
of 1–100 nanometers (nm) (McNeil, 2005), Nanomaterials
have some unique physical, chemical, and biological properties
which are fundamentally different from those of the corre-
sponding bulk material and could be widely used in medical
testing (Rosi and Mirkin, 2005). One of the possible applica-
tions of bio nanotechnology is timely diagnosis of various dis-
eases. Many infectious agents both bacterial and viral which
cause SARS, dengue, Asian ﬂu etc. spread out very fast and
cause epidemic outbreaks with a very high morbidity and
mortality. Therefore there is a great potential to use nanotech-
nology for diagnosing infectious agents.
Magnetic nanobeads as a nanosensor for clinically relevant
viruses and bacteria can be developed. The nanobeads have a
supramagnetic iron oxide core coated with dextran. Anti-viral
antibodies are conjugated directly to nanobeads. By using a
magnetic ﬁeld, as few as ﬁve viral particles can be detected
in a 10 mL serum sample. This system is more sensitive than
ELISA-based methods and is an improvement over PCR-
based detection because it is cheaper, faster and has fewer
artifacts resulting in false positives. ELISA can decrease the
lower limit of detection (LOD) of antigen detection to
1 pg/mL. Another sensitive method called real-time
immuno-polymerase chain reaction (IPCR) assay can detect
1000 HIV-1 RNA copies or 40 attograms of HIV-1 antigen
per reaction (Barletta et al., 2004).
Direct, real-time electrical detection of single virus particles
can be achieved with high selectivity by using nanowire ﬁeld
effect transistors. Measurements made with nanowire arrays
modiﬁed with antibodies for inﬂuenza A showed discrete
conductance changes characteristic of binding and unbinding
in the presence of inﬂuenza A but not paramyxovirus or
adenovirus, indicating how speciﬁc these tests are.
The rapid and sensitive detection of pathogenic bacteria is
extremely important in medical diagnosis. Limitations of most
of the conventional diagnostic methods are a lack of ultra sen-
sitivity or delay in getting results because of the culturing in-
volved. Several nanotechnology based methods have already
been described including Ferro ﬂuid magnetic nanoparticles
and ceramic nanospheres. A bio conjugated nanoparticle
based bioassay for in situ pathogen quantiﬁcation can detect
a single bacterium within 20 min.
Using nanolithography, antibodies could be localized in
an exact place or spot, however, nonspeciﬁc background
binding of the proteins and detection sensitivity is the major
problem associated with this technique. Nanotechnology
therefore helps in providing the technique that is capable
of identifying and detecting a single viral particle. High sen-
sitivity for detection is needed for diseases like AIDS for as
few as 5–10 HIV viral particles can infect the other person
and the current methods can assess either antibodies or a
high load of viral antigens.
It is also necessary to identify the antibodies quickly as
some of these infectious agents are quite stable, aggressive
and these could be easily transmitted in trace amounts. Some
of the infectious agents such as prions and infectious amyloi-
doses could be transmitted on fento molar concentration level.
Therefore, diagnostics which are capable of identifying these
infectious agents in extremely low concentration are important
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infectious agents.
2.2.3. Diagnosis of tuberculosis based on BioMEMS
In India, the country with the highest estimated number of TB
cases, nanotechnology can play a major role in addressing this
issue. The diagnostic principle of nanomechanical deﬂection of
the microcantilever due to adsorption of the TB speciﬁc anti-
gens on its upper surface is employed for the diagnosis of
TB. The deﬂection of the microcantilever would be measured
in terms of piezoresistive changes by implanting boron at the
anchor point. Such a biomicroelectromechanical system
(BioMEMS) based microdiagnostic kit is highly speciﬁc as
complementary biochemical interactions take place between
TB antigens and the antibodies against them immobilized on
the upper surface of the microcantilever. Measurement of anti-
gens up to picogram levels can be done using this technique
(Nelson et al., 2001).
NanoLogix’s ‘‘Identikit’’ has shown great promise in
detecting the presence of Mycobacterium avium complex
(MAC) infection. The methodology provides for early detec-
tion of these pathogens in sputum and stool samples; thus
allowing for treatment before the infection spreads throughout
the body. Early detection of Mycobacterium avium complex
(MAC) infection is rapidly becoming important, especially
for those with AIDS who are living longer due to new methods
of treatment.
A nanotechnology-based TB diagnostic kit, designed by the
Central Scientiﬁc Instruments Organization of India and cur-
rently in clinical trials, does not require skilled technicians
for use and offers efﬁciency, portability, user-friendliness and
availability for as little as Rs.30 per test. Polylactide co-glyco-
lide nanoparticles are being investigated by groups at the
Harvard University (U.S.), the Postgraduate Institute of
Medical Education and Research (India) and the Council for
Scientiﬁc and Industrial Research (South Africa), as drug
carriers for treating TB.
2.2.4. Nanotechnology and cardiovascular diseases
The rapid progress of nanoscience and the application of
nanotechnology are changing the foundations of diagnosis,
treatment, and prevention of cardiovascular diseases (Wickline
et al., 2006; Lipinski et al., 2004). As the core of nanotechnol-
ogy, nano- and microparticles offer ‘‘three-in-one’’ functions
as imaging agents, target probes, and therapeutic carriers.
While nano- and microparticle-based imaging of cardiovascu-
lar interventions is still in its developing phase, it has already
presented exciting potential to monitor primary interventional
procedures for precise therapeutic delivery, enhance the effec-
tiveness of delivered therapeutics, and monitor therapeutic
efﬁciency after interventions performed to treat cardiovascular
diseases (Xiaoming, 2007).3. Nanotechnology for clinical laboratory diagnostics – salient
points
With advances in diagnostic technologies, doctors will be able
to give patients complete health checks quickly and routinely.
If any medication is required this will be tailored speciﬁcally to
the individual based on their genetic makeup, thus preventingunwanted side-effects. As a result, the health system will
become preventative rather than curative
 Nanoscale particles, used as tags or labels, increase the
sensitivity, speed and ﬂexibility of biological tests
measuring the presence or activity of selected substances.
 Nanotechnology enables testing of relatively small sample
volumes.
 Many of the technologies described are applicable both to
DNA and proteins although some are better suited for
proteins in body ﬂuids.
 Nanotechnology enables the detection of a few microorgan-
isms or molecules that would not be possible with conven-
tional techniques.
 Early detection of disease such as CVD, PIH, and cancer
improves the chances of cure.
 Nanotechnology, by reducing the time required for the test,
has a positive impact on both clinical decision-making and
treatment costs.
 Nanoparticles for targeted drug delivery in cancer enable
combination of diagnostics and therapeutics and act as
adjuncts to hyperthermia and photodynamic therapy.
 Nanobiotechnology will facilitate the development of per-
sonalized medicine, i.e. prescription of speciﬁc therapeutics
best suited for an individual. The use of nanotechnologies
for diagnostic applications shows great promise to meet
the rigorous demands of the clinical laboratory for sensitiv-
ity and cost-effectiveness.
4. Insight of nano diagnostics
The biological application of nano-particles is a rapidly devel-
oping area of nanotechnology that raises new possibilities in
the diagnosis and treatment of various diseases .The applica-
tion of nanotechnology in the medical ﬁeld must conform to
requirements for public health, safety and environmental pro-
tection An important point is that, basically, what safeguards
are needed with regard to a new technology depends mainly on
the way it will be used.
 Nano particles can be much more reactive than larger vol-
umes of the same substance. They are relatively cheap and
can be manufactured in large quantities. They are already
used in consumer products and can be highly reactive. Such
particles often have unknown toxicity which can be difﬁcult
to quantify.
 Nanoparticles can cause chronic health effects. Carbon
nanotubes are strong and can have a similar shape to asbes-
tos ﬁbers; several reviews conclude that carbon nanotubes
are potentially toxic to humans. Given that nano-sized
objects tend to be more toxic than their large scale form
it would be unwise to allow the unnecessary build up of
nanoparticles within the body until the toxicological effects
of that nanoparticle are known.
 There is still too little research into the potential negative
impacts of this technology on the environment Removing
nanoparticles from the environment may also present a sig-
niﬁcant problem due to their small size. If absorbed, the
particles may travel up the food chain to larger animals
and have been shown to be harmful to Humans.
116 K.K. Alharbi, Y.A. Al-sheikh There is some concern about the safety of nanoparticles
introduced in the human body and released into the envi-
ronment. Research is underway to address these issues. As
yet there are no FDA directives to regulate nanobiotechnol-
ogy, there are some legal issues of immediate and practical
concern, related to the existing regulations in the ﬁeld of
nanodiagnostics.
The ﬁeld of nano diagnostics raises certain ethical concerns
related with the testing of blood.
 For example, if a nanochip were to be able to analyze our
entire DNA sequence from a drop of blood, would it be
morally correct for hospitals to know an individual’s entire
genetic makeup? Should not individuals have some say in
whether or not hospitals have access to these records?
Another area of concern is with the use of MEMS devices
within the body. If the capsule device breaks down in one’s
stomach, harmful metal oxide particles could cause the
introduction of free radicals that are harmful to cells.
Researchers still do not know if the introduction of these
devices within one’s body would leave residual nanoparti-
cles that would be harmful to the digestive system.Acknowledgment
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